Orphazyme soars; co discloses Goldman reduced ownership

Strategic Partners A/S

23/06/2021 16:26

** U.S.-listed shares in Orphazyme  ORPH.O  up 39.5% at $8.33
after hitting a high of $9.35 
    ** Before market open, Danish co disclosed that Goldman
Sachs had reduced its holding of Orphazyme shares to less than
5% as of June 17
    ** The day before, on June 16 Goldman’s "aggregate holding
of shares and financial instruments had increased to 5.58% of
the share capital and voting rights," the company said
 urn:newsml:reuters.com:*:nGNEbBNcj2
    ** Orphazyme, which has been a focus of retail investors on
social media, saw its shares sink on June 18 after its genetic
disorder drug candidate, arimoclomol, failed to get an approval
from the U.S. FDA  urn:newsml:reuters.com:*:nL5N2O02IL
    ** The company's U.S. shares fell 10.2% on June 17 and fell
49.7% on June 18

 (Reporting By Sinéad Carew)
 ((sinead.carew@thomsonreuters.com; +1 (646) 223 6186; Reuters
Messaging: sinead.carew.thomsonreuters.com@reuters.net))